Literature DB >> 9474685

What range of programmable AV delays is necessary in antibradycardia DDD stimulation?

G H Von Knorre1, B Ismer, W Voss, M Petzsch, K Pulya.   

Abstract

DDD pacemakers differ considerably in device specific extents of AV delay (AVD) programmability. To demonstrate the requirements of a mean DDD pacemaker patient population optimal AVDs in 200 DDD pacemaker patients (age 8 to 91 years) were estimated by left atrial electrography. The results should help to define an AVD programmability standard. Left atrial electrograms were recorded via a bipolar filtered esophageal lead. The method aims on adjusting the left atrial electrogram to 70 ms prior to the ventricular spike, both during VDD and DDD operation of the pacemaker. In atrial sensed stimulation the optimal AVD varied from 40 to 205 ms (100.5 +/- 24.5 ms) and in atrial paced stimulation from 85 to 245 ms (169.1 +/- 24.5 ms). The difference of the mean values is statistically significant (p < 0.001). The difference between both values in the individual patient, the individual AVD correction time, varied from 0 to 170 ms (68.7 +/- 26.6 ms). Thus, from our findings requirements on AV delay programmability standard can be derived: AVDs (1) should have a range from 40 to 250 ms, (2) should be independently programmable during atrial sensed and atrial paced operation, and (3) should provide as nominal settings 100 ms for atrial sensed and 170 ms for atrial paced stimulation.

Entities:  

Mesh:

Year:  1998        PMID: 9474685     DOI: 10.1111/j.1540-8159.1998.tb01101.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  2 in total

1.  Echocardiographic AV-interval optimization in patients with reduced left ventricular function.

Authors:  C Melzer; A C Borges; F Knebel; W S Richter; W Combs; G Baumann; H Theres
Journal:  Cardiovasc Ultrasound       Date:  2004-12-17       Impact factor: 2.062

2.  Prevalence of E/A wave fusion and A wave truncation in DDD pacemaker patients with complete AV block under nominal AV intervals.

Authors:  Wolfram C Poller; Henryk Dreger; Marius Schwerg; Christoph Melzer
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.